{"entity":{"id":"nct06561607","kind":"trial","name":"A Clinical Trial of TQB2102 for Injection in the Treatment of HER2 Low-Expressing Recurrent/Metastatic Breast Cancer","aka":[],"tldr":"A phase 3 trial testing TQB2102 in HR-positive / HER2-negative breast cancer, active and no longer recruiting.","summary":"A Clinical Trial of TQB2102 for Injection in the Treatment of HER2 Low-Expressing Recurrent/Metastatic Breast Cancer is a phase 3 interventional study registered as NCT06561607, led by Chia Tai Tianqing Pharmaceutical, and active but no longer recruiting on the registry. Official title: A Randomised, Open, Parallel-Controlled Phase III Clinical Trial Evaluating the Efficacy and Safety of TQB2102 for Injection Versus Investigator-Selected Chemotherapy in HER2 Low-Expressing Recurrent/Metastatic Breast Cancer. Planned enrolment is 542 participants (estimated). The study started in 2024-10-11 and primary completion is expected in 2027-01. No results have been posted on ClinicalTrials.gov.","status":"active","asOf":"2026-09-11","links":[{"label":"ClinicalTrials.gov NCT06561607","url":"https://clinicaltrials.gov/study/NCT06561607"}],"tags":["ctgov-ingest"],"related":[],"cancers":["breast-hr-positive","her2-low-metastatic-breast-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":["tqb2102"],"companies":["sino-biopharm"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06561607","phase":"3","setting":"A Randomized, Open, Parallel-Controlled Phase III Clinical Trial Evaluating the Efficacy and Safety of TQB2102 for Injection Versus Investigator-Selected Chemotherapy in HER2 Low-Expressing Recurrent/Metastatic Breast Cancer","sponsor":"Chia Tai Tianqing Pharmaceutical","participation":[{"nct":"NCT06561607","source":"https://clinicaltrials.gov/study/NCT06561607","fetchedAt":"2026-10-07T16:54:48.431Z","studySha256":"d4d57f17ba478f3cce1c5b2a03147dea9391e849a972a9156d2f7d8d91066090","overallStatus":"ACTIVE_NOT_RECRUITING","lastUpdatePosted":"2026-09-10","leadSponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","collaboratorCount":0,"minimumAge":"18 Years","maximumAge":"75 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":542,"enrolmentType":"ESTIMATED","siteCount":34,"recruitingSiteCount":0,"countries":["China"]}],"started":"2024-10-11","startedType":"actual","enrolled":542,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06561607/","neighbours":{"cancer":[{"id":"her2-low-metastatic-breast-cancer","kind":"cancer","name":"HER2-low and HER2-ultralow metastatic breast cancer","route":"/cancers/her2-low-metastatic-breast-cancer/"},{"id":"breast-hr-positive","kind":"cancer","name":"HR-positive / HER2-negative breast cancer","route":"/cancers/breast-hr-positive/"}],"drug":[{"id":"tqb2102","kind":"drug","name":"TQB2102","route":"/drugs/tqb2102/"}],"company":[{"id":"sino-biopharm","kind":"company","name":"Sino Biopharmaceutical (Chia Tai Tianqing)","route":"/companies/sino-biopharm/"}]}}